Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • EELS (Ethical Economic Legal and Social) Article
  • Published:

EELS Paper

The potential impact of pharmacogenetic testing on medication adherence

The Pharmacogenomics Journal volume 13, pages 481–483 (2013)Cite this article

Subjects

Abstract

Poor medication adherence is a well-known problem, particularly in patients with chronic conditions, and is associated with significant morbidity, mortality and health-care costs. Multi-faceted and personalized interventions have shown the greatest success. Pharmacogenetic (PGx) testing may serve as another tool to boost patients’ confidence in the safety and efficacy of prescribed medications. Here, we consider the potential impact (positively or negatively) of PGx testing on medication-taking behavior.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Wang L, McLeod HL, Weinshilboum RM . Genomics and drug response. N Engl J Med 2011; 364: 1144–1153.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. NEHI 2011, Thinking Outside the Pillbox: A System-wide Approach to Improving Patient Medication Adherence for Chronic Disease http://www.nehi.net/uploads/full_report/pa_issue_brief__final.pdf.

  3. Osterberg L, Blaschke T . Adherence to medication. N Engl J Med 2005; 353: 487–497.

    Article  CAS  PubMed  Google Scholar 

  4. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS . Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005; 43: 521–530.

    Article  PubMed  Google Scholar 

  5. Fischer MA, Stedman MR, Lii J, Vogeli C, Shrank WH, Brookhart MA et al. Primary medication non-adherence: analysis of 195,930 electronic prescriptions. J Gen Intern Med 2010; 25: 284–290.

    Article  PubMed  PubMed Central  Google Scholar 

  6. McGough JJ . Attention-deficit/hyperactivity disorder pharmacogenomics. Biol Psychiatry 2005; 57: 1367–1373.

    Article  CAS  PubMed  Google Scholar 

  7. Grant RW, Hivert M, Pandiscio JC, Florez JC, Nathan DM, Meigs JB . The clinical application of genetic testing in type 2 diabetes: a patient and physician survey. Diabetologia 2009; 52: 2299–2305.

    Article  CAS  PubMed  Google Scholar 

  8. Charland SL, Agatep BC, Epstein RS, Frueh FW, Herrera V, Devlin J et al. Patient knowledge of pharmacogenetic information improves adherence to statin therapy: results of the additional Kif6 risk offers better adherence to statins (Akrobats) trial. J Am Coll Cardiol 2012; 59: E1848–E1848.

    Article  Google Scholar 

  9. WHO. Adherence to Long-Term Therapies: Evidence for Action. World Health Organization: Geneva, 2003. http://www.who.int/chp/knowledge/publications/adherence_report/en/.

  10. Kreps GL, Villagran MM, Zhao X, McHorney CA, Ledford C, Weathers M et al. Development and validation of motivational messages to improve prescription medication adherence for patients with chronic health problems. Patient Educ Couns 2011; 83: 375–381.

    Article  PubMed  Google Scholar 

  11. Kripalani S, Gatti ME, Jacobson TA . Association of age, health literacy, and medication management strategies with cardiovascular medication adherence. Patient Educ Couns 2010; 81: 177–181.

    Article  PubMed  Google Scholar 

  12. Piette JD, Heisler M, Wagner TH . Cost-related medication underuse: do patients with chronic illnesses tell their doctors? Arch Inter Med 2004; 164: 1749–1755.

    Article  Google Scholar 

  13. Lemstra M, Blackburn D, Crawley A, Fung R . Proportion and risk indicators of nonadherence to statin therapy: a meta-analysis. Can J Cardiol 2012; 28: 574–580.

    Article  PubMed  Google Scholar 

  14. Kripalani S, Yao X, Haynes RB . Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med 2007; 167: 540–550.

    Article  PubMed  Google Scholar 

  15. Bosworth HB, Granger BB, Mendys P, Brindis R, Burkholder R, Czajkowski SM et al. Medication adherence: a call for action. Am Heart J 2011; 162: 412–424.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X . Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008: CD000011.

  17. Schroeder K, Fahey T, Ebrahim S . Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings. Cochrane Database Syst Rev 2004; 2: CD004804.

    Google Scholar 

  18. van Bokhoven MA, Koch H, van der Weijden T, Grol RP, Kester AD, Rinkens PE et al. Influence of watchful waiting on satisfaction and anxiety among patients seeking care for unexplained complaints. Ann Fam Med 2009; 7: 112–120.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Trachtenberg F, Dugan E, Hall MA . How patients’ trust relates to their involvement in medical care. J Fam Practice 2005; 54: 344–352.

    Google Scholar 

  20. Dowell J, Hudson H . A qualitative study of medication-taking behaviour in primary care. Fam Pract 1997; 14: 369–375.

    Article  CAS  PubMed  Google Scholar 

  21. Bevan JL, Lynch JA, Dubriwny TN, Harris TM, Achter PJ, Reeder AL et al. Informed lay preferences for delivery of racially varied pharmacogenomics. Genet Med 2003; 5: 393–399.

    Article  PubMed  Google Scholar 

  22. Shah RR, Shah DR . Personalized medicine: is it a pharmacogenetic mirage? Br J Clin Pharmacol 2012; 74: 698–721.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Hresko A, Haga S . Insurance coverage policies for personalized medicine. J Pers Med 2012; 2: 201–216.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Almarsdottir AB, Bjornsdottir I, Traulsen JM . A lay prescription for tailor-made drugs—focus group reflections on pharmacogenomics. Health Policy 2005; 71: 233–241.

    Article  PubMed  Google Scholar 

  25. Issa AM, Tufail W, Hutchinson J, Tenorio J, Baliga MP . Assessing patient readiness for the clinical adoption of personalized medicine. Public Health Genomics 2009; 12: 163–169.

    Article  CAS  PubMed  Google Scholar 

  26. Rogausch A, Prause D, Schallenberg A, Brockmoller J, Himmel W . Patients’ and physicians’perspectives on pharmacogenetic testing. Pharmacogenomics 2006; 7: 49–59.

    Article  PubMed  Google Scholar 

  27. Trosman JR, Van Bebber SL, Phillips KA . Coverage policy development for personalized medicine: private payer perspectives on developing policy for the 21-gene assay. J Oncol Pract 2010; 6: 238–242.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Jorgensen AL, Hughes DA, Hanson A, van Eker D, Toh CH, Pirmohamed M et al. Adherence and variability in warfarin dose requirements: assessment in a prospective cohort. Pharmacogenomics 2013; 14: 151–163.

    Article  CAS  PubMed  Google Scholar 

  29. Nielsen-Bohlman L, Institute of Medicine (US). Committee on Health Literacy Health Literacy: A Prescription to End Confusion. National Academies Press: Washington, DC, 2004, xix, p 345.

    Google Scholar 

  30. Galesic M, Garcia-Retamero R . Statistical numeracy for health: a cross-cultural comparison with probabilistic national samples. Arch Intern Med 2010; 170: 462–468.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by funding from the US National Institutes of Health 5R01-GM081416-05.

Author information

Authors and Affiliations

  1. Institute for Genome Sciences and Policy, Duke University, Durham, NC, USA

    S B Haga

  2. Duke Clinical Research Institute, Duke University, Durham, NC, USA

    N M A LaPointe

Authors
  1. S B Haga
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N M A LaPointe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S B Haga.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Cite this article

Haga, S., LaPointe, N. The potential impact of pharmacogenetic testing on medication adherence. Pharmacogenomics J 13, 481–483 (2013). https://doi.org/10.1038/tpj.2013.33

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/tpj.2013.33

Keywords

This article is cited by

Search

Advanced search

Quick links